Granted Patent B2

US 12,440,644 · App. 17/617,822 · Granted Oct 14, 2025

Inventors: Michael G. Murray (Ballina, IE); Horacio Montes de Oca (Ballina, IE); Malford E. Cullum (Grayslake, IL); Gary W. Inglese (Deerfield, IL); Rory Grogan (Dublin, IE)

Assignee: Hollister Incorporated

A61M25/002A61L2/18A61M25/0045A61L2202/122A61L2202/18A61L2202/24A61M2025/0019A61M2025/0046A61M2025/0056

Abstract

Claims (9)

1. A reusable urinary catheter product comprising:

a case comprising a distal section, a proximal section, and a flexible middle section therebetween, wherein the middle section of the case comprises grooves and ridges and is configured to bend, the case defining a cavity and the distal section of the case including at least one cutout on an outer surface of the case, and wherein one or more of zinc oxide, zinc sulphates, or zero valence silver is compounded into a material of the case;

a hydration fluid within the cavity, the hydration fluid comprising a sterilization medium;

a reusable catheter including a catheter shaft having a distal end and a proximal end, the catheter including a hydrophilic coating thereon, wherein the hydration fluid hydrates and sterilizes the catheter, the catheter being configured to be repeatedly inserted into and removed from the case; and

a cap associated with distal end portion of the catheter shaft, wherein a lower section of the cap engages the at least one cutout of the case.

2. The product of claim 1 wherein the hydration fluid comprises at least one of: an anti-septic lubricant, a water-based solution of chlorhexidine, an oil-based lubricating agent, FimH inhibitors, antibacterial materials, nanoparticles with bactericidal effects, oxazolidinones, antibacterial proteins, a water solution with honey, glucose oxidase, a water solution with silver, a solution of polyvinyl pyrrolidone (PVP) and iodine, or a water lubricant with a surfactant configured to loosen a biofilm from the catheter.

3. The product of claim 1 , wherein one or more of zinc oxide, zinc sulphates, or zero valence silver is incorporated into the the catheter.

4. The product of claim 2 , wherein the FimH inhibitors include mannose based molecules comprising one or more of alkyl alfa-D-mannopyranosides, or aryl alfa-D-mannopyranosides.

5. The product of claim 2 , wherein the antibacterial materials include peptidomimetic antimicrobials comprising one or more of (KLAKLAK)2, D-(KLAKLAK)2, brilacidin (PMX-30063), or POL7080.

Assignments (1)

Continuity (2)

References Cited (235)